Uvax Bio Australia

Uvax Bio is a clinical-stage biotechnology company specializing in the development of next-generation vaccines for infectious diseases using a proprietary protein nanoparticle platform. Spun off from Scripps Research, the company utilizes its one-component self-assembling protein nanoparticle (1c-SApNP) technology to create vaccines that display a high density of stabilized antigens, mimicking the structure of native viruses. Their primary focus is on developing a preventative HIV vaccine, with two lead candidates currently in Phase 1 clinical trials. Beyond HIV, Uvax Bio is leveraging its platform to address other global health threats, including COVID-19, influenza, and RSV.